Search - tctmd.com

Displaying 181 - 200 of 659

Sort: Relevancy | Date

Presentation TCT 2017

The Potential For BRS: What Weve Learned From Pushing The Envelope

Presenter: Stephen G. Ellis, Takeshi Kimura, Corrado Tamburino

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB SCAAR

Presenter: Stephen G. Ellis, Takeshi Kimura, Stefan K. James

October 31, 2017

Presentation TCT 2017

Registry Update: BVS STEMI STRATEGY

Presenter: Stephen G. Ellis, Takeshi Kimura, Alfonso Ielasi

October 31, 2017

Presentation TCT 2017

Registry Update: IT-DISAPPEARS

Presenter: Stephen G. Ellis, Takeshi Kimura, Francesco Bedogni

October 31, 2017

Presentation TCT 2017

Registry Update: FRANCE ABSORB

Presenter: Stephen G. Ellis, Takeshi Kimura, Didier Carrié

October 31, 2017

Presentation TCT 2017

Registry Update: GABI-R

Presenter: Stephen G. Ellis, Takeshi Kimura, Holger M. Nef

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB UK

Presenter: Stephen G. Ellis, Takeshi Kimura, Mark A. de Belder

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB Extend At 3 Years

Presenter: Stephen G. Ellis, Takeshi Kimura, Antonio L. Bartorelli

October 31, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Presentation TCT 2017

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Presenter: Azeem Latib, Joanna J. Wykrzykowska

October 31, 2017

Presentation TCT 2017

Bioresorbable Scaffolds One Year After Approval: FDA Perspectives on Current and Future BRS

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Andrew Farb

October 31, 2017

Presentation TCT 2017

Bioresorbable Scaffolds One Year After Approval: Physician-scientist Perspectives on Current and Future BRS

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

Presenter: Stephan Achenbach, Jacques J. Koolen, Stefan Verheye

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Short DAPT IDE Trials

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee

October 31, 2017

Presentation TCT 2017

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

Presenter: Stephan Achenbach, Jacques J. Koolen, Bo Xu

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane

October 31, 2017

Advertisement

The Potential For BRS: What Weve Learned From Pushing The Envelope

Registry Update: ABSORB SCAAR

Registry Update: BVS STEMI STRATEGY

Registry Update: IT-DISAPPEARS

Registry Update: FRANCE ABSORB

Registry Update: GABI-R

Registry Update: ABSORB UK

Registry Update: ABSORB Extend At 3 Years

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Bioresorbable Scaffolds One Year After Approval: FDA Perspectives on Current and Future BRS

Bioresorbable Scaffolds One Year After Approval: Physician-scientist Perspectives on Current and Future BRS

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

FDA Perspectives on Short DAPT IDE Trials

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content